The adult vaccines market comprises vaccines administered to individuals aged 18 years or above. Some of the commonly used adult vaccines include influenza, pneumococcal, meningococcal, hepatitis, human papilloma virus (HPV), and herpes zoster (shingles) vaccines. These vaccines help prevent various infectious diseases and improve the overall health of adults. Influenza vaccines help provide protection against seasonal influenza, while pneumococcal vaccines help prevent pneumococcal pneumonia and related infections. The meningococcal vaccine provides immunization against meningococcal disease that can potentially lead to meningitis or sepsis. Adult vaccines also include hepatitis A & B and HPV vaccines that protect against liver infection and cervical cancer, respectively. There is a growing awareness among adults regarding the importance of immunization against different infectious diseases. This has boosted the demand for adult vaccines over the years.

The Global Adult Vaccines Market is estimated to be valued at US$ 16,790.11 Mn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the adult vaccines market are GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc. GlaxoSmithKline Plc leads the adult vaccine market with its influenza, meningococcal disease, and shingles vaccines.

There is growing awareness among adults about the importance of immunization against different infectious diseases. Recommended adult vaccination helps increase immunity and reduces health risks. Factors such as the risk of seasonal influenza, rising virus mutations, greater vaccine acceptance, and recommendations by health authorities are fueling the demand for adult vaccines globally.

Changing lifestyles have increased the risk of several chronic diseases among adults. Advancements in vaccine technologies are allowing the development of novel adult vaccines against disease indications such as HIV, respiratory syncytial virus (RSV), and tuberculosis. This is expected to further boost the market during the forecast period.

Market Trends

Combination Vaccines - Manufacturers are focusing on developing combination vaccines that protect against multiple infectious diseases through a single vaccination. This offers greater patient compliance over separate vaccines.

Growing Immunization Programs - There is a rising focus on National Immunization Programs for adults all over the world. This is expected to significantly drive the adult vaccination rates in the coming years.

Market Opportunities

HIV Adult Vaccine - There is no licensed preventive HIV vaccine available till date. Successful development of an HIV vaccine can open significant opportunities.

RSV Adult Vaccine - Respiratory syncytial virus (RSV) is a major cause of respiratory disease in older adults. A safe and effective RSV vaccine can address a large unmet need.

Impact of COVID-19 on Adult Vaccines Market Growth
The COVID-19 pandemic has significantly impacted the adult vaccines market growth. During the initial phase of the pandemic, major focus was given to contain the spread of the virus. Many regular adult vaccination programs were temporarily halted or postponed to avoid overcrowding in hospitals and clinics. Supply chain disruptions also affected the production and distribution of various adult vaccines. However, with time many countries learnt to live with the new normal and vaccination programs gradually resumed with safety protocols. Telehealth and online appointment booking tools helped to increase access while maintaining social distancing. Remote monitoring technologies assisted healthcare workers to track vaccination status of at-risk groups. While the adult vaccination uptake saw a decline in 2020, in the recent times demand has picked up pace again. Manufacturers are also scaling up production capacities to fulfill the growing demand. However, future strategies need to consider flexible contingency plans to tackle future pandemics or healthcare crises without major disruptions to vaccination programs.

Impact by Geographical Regions

In terms of value, the North American region holds the major share of the global adult vaccines market, followed by Europe. This is attributed to developed healthcare infrastructure, availability of reimbursement schemes and awareness levels regarding vaccination in these regions. However, the Asia Pacific region is predicted to witness the fastest growth during the forecast period owing to improving economic conditions, rising healthcare spending and increasing focus of manufacturers on emerging countries. India and China are poised to offer lucrative opportunities for market players due to their huge population base and gradual shift towards preventive healthcare approach. Initiatives by various governments to strengthen immunization programs will further augment the regional market growth in future.